
    
      A 2 arm (1 Active, 1 Active Control) study is to compare the safety and efficacy of different
      induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal
      transplant recipients treated with tacrolimus, MMF and a rapid steroid withdrawal.
    
  